Merck gets positive EMA Committee opinion for Keytruda plus Gemcitabine, Cisplatin for Biliary Tract Cancer Ruchika Sharma14 Nov 2023 2:00 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the European Medicines Agency's Committee for Medicinal...
Merck bags USFDA nod for Keytruda plus gemcitabine, cisplatin to treat Biliary Tract Cancer Ruchika Sharma2 Nov 2023 2:30 PM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
MSD wins DCGI nod for Keytruda for treatment of triple negative breast cancer, renal cell carcinoma Ruchika Sharma26 Oct 2023 11:32 AM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
European Commission nod to Merck Keytruda for non-small cell lung cancer at high risk of recurrence Ruchika Sharma17 Oct 2023 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Commission (EC) has approved KEYTRUDA,...
Merck gets USFDA nod for neoadjuvant/ adjuvant Keytruda for resectable non-small cell lung cancer Ruchika Sharma17 Oct 2023 12:54 PM ISTThe approval marks the sixth NSCLC indication for KEYTRUDA.
Merck Keytruda met primary endpoint of disease free survival in certain patients with Muscle-Invasive Urothelial Carcinoma after surgery Ruchika Sharma10 Oct 2023 11:30 AM ISTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck Keytruda plus Padcev improves survival in advanced or metastatic urothelial carcinoma Ruchika Sharma24 Sept 2023 3:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced positive topline results from the Phase 3 KEYNOTE-A39...
Setback: Merck-Eisai combination therapy fails in lung cancer studies Ruchika Sharma23 Sept 2023 2:21 PM ISTNew Jersy: Drugmakers Merck and Eisai said on Friday a combination of their cancer therapies did not prolong the lives of patients in two...
Merck gets USFDA priority review for Keytruda plus concurrent chemoradiotherapy for cervical cancer Ruchika Sharma21 Sept 2023 5:33 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Merck gets positive EU CHMP opinion for Keytruda as adjuvant treatment for adults with Non-Small Cell Lung Cancer Ruchika Sharma18 Sept 2023 11:30 AM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sept 2023 2:30 PM ISTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Merck, Portage Biotech collaborate to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda in solid tumors Ruchika Sharma10 Sept 2023 11:30 AM ISTWestport: Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in...
